Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on May 13, 2002

Circulation. 2002
Published online before print May 13, 2002, doi: 10.1161/01.CIR.0000017860.20619.23
A more recent version of this article appeared on June 11, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/23/2766    most recent
01.CIR.0000017860.20619.23v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Weissleder, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chen, J.
Right arrow Articles by Weissleder, R.
Related Collections
Right arrow Restenosis
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Imaging
Right arrow Catheter-based coronary and valvular interventions: other
Right arrow Coronary imaging: angiography/ultrasound/Doppler/CC
Right arrow Acute coronary syndromes
Right arrow Other diagnostic testing
Right arrow Acute myocardial infarction
Right arrow Acute Stroke Syndromes
Right arrow Carotid Stenosis
Right arrow Other imaging
Right arrow Chronic ischemic heart disease
Right arrow Mechanism of atherosclerosis/growth factors

Submitted on January 10, 2002
Revised on March 26, 2002
Accepted on March 27, 2002

In Vivo Imaging of Proteolytic Activity in Atherosclerosis

Jiqiu Chen MD, Ching-Hsuan Tung PhD, Umar Mahmood MD, PhD, Vasilis Ntziachristos MD, Robert Gyurko PhD, Mark C. Fishman MD, Paul L. Huang MD, PhD, and Ralph Weissleder MD, PhD*

From the Center for Molecular Imaging Research (C.-H.T., U.M., V.N., R.W.) and the Cardiovascular Research Center and Cardiology Division (J.C., R.G., M.C.F., P.L.H.), Massachusetts General Hospital, Harvard Medical School, Boston.

* To whom correspondence should be addressed. E-mail: weissleder{at}helix.mgh.harvard.edu.

Background—Atherosclerotic plaque rupture, the most important cause of acute cardiovascular incidents, has been strongly associated with vascular inflammation. On the basis of the hypothesis that the inflammatory response and proteolysis lead to plaque rupture, we have examined the role of cathepsin B as a model proteolytic enzyme.

Methods and Results—Using western-type diet--fed apoE and apoE/endothelial NO synthase double knockout mice as models of atherosclerosis, we show (1) that cathepsin B is upregulated in atherosclerotic lesions characterized by high degrees of inflammation compared with normal aorta or silent lesions, (2) that intravenously injectable novel cathepsin B imaging beacons are highly activated within active atherosclerotic lesions and colocalize with cathepsin B immunoreactivity, and (3) that cathepsin B activity in atherosclerotic lesions can be imaged in whole animals by using a novel near-infrared tomographic imaging system.

Conclusions—These studies indicate that cathepsin B, and potentially other proteases, may serve as a biomarker for vulnerable plaques when probed with beacons. The tomographic in vivo imaging method as well as catheter-based optical sensing methods could be readily adapted to screening and potentially to the molecular profiling of a number of proteases in vulnerable plaque in vivo.


Key words: atherosclerosis • enzymes • cathepsin B • imaging